Department of Ophthalmology, Erasmus Medical Center, Rotterdam, the Netherlands.
Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.
JAMA Ophthalmol. 2021 Jun 1;139(6):601-609. doi: 10.1001/jamaophthalmol.2021.0497.
Uncertainty currently exists about whether the same genetic variants are associated with susceptibility to low myopia (LM) and high myopia (HM) and to myopia and hyperopia. Addressing this question is fundamental to understanding the genetics of refractive error and has clinical relevance for genotype-based prediction of children at risk for HM and for identification of new therapeutic targets.
To assess whether a common set of genetic variants are associated with susceptibility to HM, LM, and hyperopia.
DESIGN, SETTING, AND PARTICIPANTS: This genetic association study assessed unrelated UK Biobank participants 40 to 69 years of age of European and Asian ancestry. Participants 40 to 69 years of age living in the United Kingdom were recruited from January 1, 2006, to October 31, 2010. Of the total sample of 502 682 participants, 117 279 (23.3%) underwent an ophthalmic assessment. Data analysis was performed from December 12, 2019, to June 23, 2020.
Four refractive error groups were defined: HM, -6.00 diopters (D) or less; LM, -3.00 to -1.00 D; hyperopia, +2.00 D or greater; and emmetropia, 0.00 to +1.00 D. Four genome-wide association study (GWAS) analyses were performed in participants of European ancestry: (1) HM vs emmetropia, (2) LM vs emmetropia, (3) hyperopia vs emmetropia, and (4) LM vs hyperopia. Polygenic risk scores were generated from GWAS summary statistics, yielding 4 sets of polygenic risk scores. Performance was assessed in independent replication samples of European and Asian ancestry.
Odds ratios (ORs) of polygenic risk scores in replication samples.
A total of 51 841 unrelated individuals of European ancestry and 2165 unrelated individuals of Asian ancestry were assigned to a specific refractive error group and included in our analyses. Polygenic risk scores derived from all 4 GWAS analyses were predictive of all categories of refractive error in both European and Asian replication samples. For example, the polygenic risk score derived from the HM vs emmetropia GWAS was predictive in the European sample of HM vs emmetropia (OR, 1.58; 95% CI, 1.41-1.77; P = 1.54 × 10-15) as well as LM vs emmetropia (OR, 1.15; 95% CI, 1.07-1.23; P = 8.14 × 10-5), hyperopia vs emmetropia (OR, 0.83; 95% CI, 0.77-0.89; P = 4.18 × 10-7), and LM vs hyperopia (OR, 1.45; 95% CI, 1.33-1.59; P = 1.43 × 10-16).
Genetic risk variants were shared across HM, LM, and hyperopia and across European and Asian samples. Individuals with HM inherited a higher number of variants from among the same set of myopia-predisposing alleles and not different risk alleles compared with individuals with LM. These findings suggest that treatment interventions targeting common genetic risk variants associated with refractive error could be effective against both LM and HM.
目前尚不确定相同的遗传变异是否与低度近视(LM)和高度近视(HM)以及近视和远视的易感性相关。解决这个问题对于理解屈光不正的遗传学至关重要,并且对基于基因型预测 HM 风险的儿童和识别新的治疗靶点具有临床意义。
评估一组常见的遗传变异是否与 HM、LM 和远视的易感性相关。
设计、地点和参与者:这项遗传关联研究评估了欧洲和亚洲血统的年龄在 40 至 69 岁之间的英国生物库中无血缘关系的参与者。2006 年 1 月 1 日至 2010 年 10 月 31 日期间,从英国招募了年龄在 40 至 69 岁的参与者。在总样本量为 502682 名参与者中,有 117279 名(23.3%)接受了眼科评估。数据分析于 2019 年 12 月 12 日至 2020 年 6 月 23 日进行。
定义了四个屈光不正组:HM,-6.00 屈光度(D)或以下;LM,-3.00 至-1.00 D;远视,+2.00 D 或更高;和正视,0.00 至+1.00 D。在欧洲血统的参与者中进行了四项全基因组关联研究(GWAS)分析:(1)HM 与正视相比,(2)LM 与正视相比,(3)远视与正视相比,以及(4)LM 与远视相比。从 GWAS 汇总统计数据中生成多基因风险评分,生成了四组多基因风险评分。在欧洲和亚洲血统的独立复制样本中评估了性能。
复制样本中多基因风险评分的优势比(OR)。
共有 51841 名无血缘关系的欧洲血统个体和 2165 名无血缘关系的亚洲血统个体被分配到特定的屈光不正组,并纳入我们的分析。从所有 4 项 GWAS 分析中得出的多基因风险评分可预测欧洲和亚洲复制样本中所有类别的屈光不正。例如,HM 与正视 GWAS 得出的多基因风险评分可预测欧洲样本中的 HM 与正视(OR,1.58;95%CI,1.41-1.77;P=1.54×10-15)以及 LM 与正视(OR,1.15;95%CI,1.07-1.23;P=8.14×10-5)、远视与正视(OR,0.83;95%CI,0.77-0.89;P=4.18×10-7)和 LM 与远视(OR,1.45;95%CI,1.33-1.59;P=1.43×10-16)。
HM、LM 和远视以及欧洲和亚洲样本之间存在遗传风险变异共享。与 LM 患者相比,HM 患者从同一组近视易感性等位基因中遗传了更多的变异,而不是不同的风险等位基因。这些发现表明,针对与屈光不正相关的常见遗传风险变异的治疗干预可能对 LM 和 HM 都有效。